248: The next CRISPR fight, cheaper insulin, & an FDA shuffle

Our colleague Allison DeAngelis joins us to explain how the latest CRISPR breakthrough is shaping up to be a free-for-all among a multitude of companies and labs, including some of the biggest names in biotech. We also discuss the latest news in the life sciences, including Eli Lilly slashing the cost of insulin, succession at the FDA, and how pandemic boom times have turned to bust.

Episode metadata supplied by the publisher feed · Published Mar 2, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

248: The next CRISPR fight, cheaper insulin, & an FDA shuffle

0:00 28:36

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Readout Loud?

This episode is 28 minutes long.

When was this The Readout Loud episode published?

This episode was published on March 2, 2023.

Can I download this The Readout Loud episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!